Pellegrino Musto

Full Professor of Hematology

University of Bari Aldo Moro
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (22)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

The therapeutic landscape for multiple myeloma has gradually expanded in recent decades, leading to unprecedented deep and sustained responses as well as remarkable improvements in patient survival. Nonetheless, changes in treatment algorithms have raised new demands for patients with relapsed/refractory disease, as prior exposure and refractoriness to prior therapies impact the choice of subsequent treatments. In particular, refractoriness to lenalidomide—an established backbone of treatment in both front-line and maintenance settings and a key component of many approved regimens used in relapsed disease—is associated with suboptimal clinical outcomes. Therefore, identifying the most appropriate management in lenalidomide-refractory patients, and even more so in patients who are refractory to more than one agent, is critical. At present, treatment options for this growing subgroup of patients are still limited; however, recent data from clinical research are promising. Herein, we summarized the currently available treatment options and discuss future directions based on the latest results from ongoing clinical trials.

Year:

2025

Year:

2025

Year:

2025

Background: In the randomized, phase-3 IKEMA trial, the triplet isatuximab, carfilzomib, and dexamethasone (IsaKd) demonstrated superior clinical benefit compared to those of carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma after 1–3 prior treatments. Methods: Our real-world, AENEID study aimed to evaluate the efficacy and safety of IsaKd in patients who relapsed after frontline lenalidomide treatment, poorly represented in the IKEMA trial. Specifically, in the present multicenter analysis, we enrolled eighty-two patients who received, between April 2022 and September 2024 and outside of clinical trials, at least one cycle of IsaKd as a second-line treatment at the first relapse after induction therapy, autologous stem cell transplantation (ASCT), and lenalidomide maintenance. Results: After a median follow-up time of 12.9 months (range, 1–77), the overall response rate, at least a very good partial response rate, and median progression-free survival time were 79.3%, 56.1%, and 24.4 months, respectively. This slightly lower performance compared to that in the IKEMA study may be attributed to the well-known poor prognostic impact of lenalidomide refractoriness (len-R), developed by all our patients during maintenance therapy, and to a higher proportion of patients with extramedullary disease present in our series, which was identified as the only factor significantly affecting the PFS in multivariable analysis. The median overall survival was not reached, as in the pivotal trial, while the 1-year survival probability was 85.1%. Regarding the safety profile, our findings were consistent with those of the IKEMA trial, with no new safety signals reported. Conclusions: These real-world data support the use of IsaKd as a valuable option for len-R MM patients relapsing after the first-line therapy, including ASCT and lenalidomide maintenance.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (30)

Cristina Santoro

Sapienza University of Rome

ITALY
View details

Maria Teresa Petrucci

-

ITALY
View details

Monica Bocchia

University of Siena

ITALY
View details

Francesca Gay

Associate Professor

University of Turin

ITALY
View details

Davide Fiore Bavaro

IRCCS Humanitas Research Hospital

ITALY
View details

Mario Delia

University of Bari Aldo Moro

ITALY
View details

Valerio De Stefano

Full Professor of Hematology

Università Cattolica del Sacro Cuore

ITALY
View details

Roman Hajek

University of Ostrava

CZECH REPUBLIC
View details

Renato Zambello

Professore associato

University of Padova

ITALY
View details

Paolo Corradini

Full Professor of Hematology

University of Milan

ITALY
View details

Francesca Palandri

IRCCS Azienda Ospedaliero-Universitaria di Bologna

ITALY
View details

Loreto Gesualdo

-

ITALY
View details

Tiziana Annese

Professore Associato

Università LUM Giuseppe Degennaro

ITALY
View details

Mauro Krampera

Docenti di ruolo di Ia fascia

University of Verona

ITALY
View details

MICHELE CAVO

University of Bologna

ITALY
View details

Fabrizio Pane

Università degli Studi di Napoli Federico II

ITALY
View details

Luca Arcaini

Director of Division of Hematology

Fondazione IRCCS Policlinico San Matteo

ITALY
View details

Giuseppe Alberto Maria PALUMBO

Associate Professor of Hematology

Università degli Studi di Napoli Federico II

ITALY
View details

Giuseppe Avvisati

Full Professor of Hematolgy

Università Campus Bio-Medico di Roma

ITALY
View details

Antonio d’Amati

-

ITALY
View details

Francesco Di Gennaro

Prof

University of Bari Aldo Moro

ITALY
View details

Giuseppe Ingravallo

Prof

University of Bari Aldo Moro

ITALY
View details

Donato Mannina

Head of Hematology Division

Azienda Ospedale Università Padova

ITALY
View details

Patrizia Chiusolo

Università Cattolica del Sacro Cuore

ITALY
View details

Francesco Albano

University of Bari Aldo Moro

ITALY
View details

Domenico Ribatti

-

ITALY
View details

Alfredo Di Leo

University of Bari

ITALY
View details

Roberto TAMMA

Professore Associato BIO/16

University of Bari Aldo Moro

ITALY
View details

Yasuhito Nannya

Professor

Kyoto University

JAPAN
View details

ANNALISA CHIAPPELLA

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details